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Abstract
Background: To better evaluate and improve the efficacy of dendritic cell (DC)-based cancer immunotherapy,
we conducted a clinical study of patients with advanced colorectal cancer using carcinoembryonic antigen
(CEA)-pulsed DCs mixed with tetanus toxoid and subsequent interleukin-2 treatment. The tetanus toxoid in
the vaccine preparation serves as an adjuvant and provides a non-tumor specific immune response to enhance vaccine
efficacy. The aims of this study were to (1) evaluate the toxicity of this treatment, (2) observe the clinical responses of
vaccinated patients, and (3) investigate the immune responses of patients against CEA before and after treatment.
Methods: Twelve patients were recruited and treated in this phase I clinical study. These patients all had metastatic
colorectal cancer and failed standard chemotherapy. We first subcutaneously immunized patients with metastatic
colorectal cancer with 1 × 106 CEA-pulsed DCs mixed with tetanus toxoid as an adjuvant. Patients received 3 successive
injections with 1 × 106 CEA-pulsed DCs alone. Low-dose interleukin-2 was administered subcutaneously following the
final DC vaccination to boost the growth of T cells. Patients were evaluated for adverse event and clinical
status. Blood samples collected before, during, and after treatment were analyzed for T cell proliferation
responses against CEA.
Results: No severe treatment-related side effects or toxicity was observed in patients who received the regular 4 DC
vaccine injections. Two patients had stable disease and 10 patients showed disease progression. A statistically
significant increase in proliferation against CEA by T cells collected after vaccination was observed in 2 of 9 patients.
Conclusions: The results of this study indicate that it is feasible and safe to treat colorectal cancer patients using this
protocol. An increase in the anti-CEA immune response and a clinical benefit was observed in a small fraction of
patients. This treatment protocol should be further evaluated in additional colorectal cancer patients with modifications
to enhance T cell responses.
Trial registration: ClinicalTrials.gov (identifier NCT00154713), September 8, 2005
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Background
Colorectal cancer (CRC) is one of the most common
and deadly cancers in Taiwan and the United States [1].
Although recent developments in surgical management,
chemotherapy, and biological therapy have improved the
survival of early-stage CRC patients, the treatment of
patients with late-stage CRC remains difficult [2]. The
use of an anti-immune checkpoint antibody has revolu-
tionized the clinical treatment of many cancers [3].
Indications for melanoma and non-small cell lung car-
cinoma have been approved, and the application of anti-
checkpoint antibodies in other cancer types, including
CRC, has been actively evaluated in the clinical setting
[4–6]. However, the results of several clinical studies re-
vealed that anti-immune checkpoint antibodies for many
cancers may not function as effectively as in melanoma
and lung cancers [7].
For CRC, a better therapeutic result was observed in
patients with mismatch-repair deficiency than in those
without this deficiency [8]. Recent reports suggested a
positive relationship between clinical responses and the
amounts of tumor mutation or neoantigen in patients
receiving anti-immune checkpoint antibody therapy [9]. It
has been hypothesized that CRC patients with mismatch-
repair deficiency may accumulate a larger number of
mutations and generate abundant neoantigens in their
tumors, thus favoring an approach involving the reactiva-
tion of pre-existing T cells using the anti-immune check-
point antibody. However, patients with mismatch-repair
deficiency represent a very small fraction of CRC patients
[10, 11]. Therefore, efforts to combine the anti-immune
checkpoint antibody with other types of treatment have
been proposed to increase the therapeutic efficacy for can-
cers displaying a lower response rate when treated with
anti-immune checkpoint antibody alone [12]. One of the
these approaches involves vaccinating CRC and other
cancer patients with tumor-associated antigens to increase
the number or diversity of T cells and followed by pro-
viding an anti-immune checkpoint antibody to strengthen
or prolong T cell responses [6, 13, 14]. The dendritic cell
(DC)-based cancer vaccine appears to be the most promi-
sing method for boosting the patient immune responses
against tumors. DCs are the most important antigen-
presenting cells in the body, and DC-based cancer im-
munotherapy has been extensively explored in recent
years [15, 16]. Provenge (sipuleucel-T), a product based
on antigen-pulsed antigen-presenting cells for the treat-
ment of hormone-refractory prostate cancer, was ap-
proved by the FDA in 2010 [17], demonstrating the
therapeutic potential of such application.
To develop an alternative therapy for patients who
have failed standard chemotherapy and provide an ef-
fective adjuvant therapy for cancer patients, DC-based
immunotherapy for CRC patients has been examined
[18]. Elevated expression of carcinoembryonic antigen
(CEA) was observed in most CRC both in the serum
and tumor [19]. Although CEA is also expressed in nor-
mal colon epithelial cells, the expression level is low.
Previous immunotherapies targeting CEA have shown
that immune responses against CEA were elevated in pa-
tients without severe autoimmune responses [20, 21], sug-
gesting that CEA may be useful as a tumor-associated
antigen. In our previous pilot study, we pulsed patient’s
autologous DCs with synthetic peptides representing the
CTL epitopes on CEA. All patients tolerated the intrano-
dal injections of DC vaccines well and no severe toxicity
or autoimmunity was observed. An increase in the num-
ber of CEA-specific T cells after DC vaccination was de-
tected in 6 of the 9 patients evaluated [20]. Two of 10
patients had stable diseases. The results of this pilot trial
suggested that the vaccination procedure is feasible and
safe, and that this treatment may generate or boost
tumor-antigen-specific T cell responses in many patients.
Studies by others and us indicated that tumor-associated
antigen-specific T cells responses can be generated in most
cancer patients after DC vaccination, but these T cell re-
sponses are generally short-lived [20, 22, 23]. This may sig-
nificantly limit treatment efficacy. In our previous pilot
study [20], we chose to use synthetic peptides representing
the CTL epitopes on CEA as the source of antigen to
pulse DCs. This approach has the benefit of generating
CEA peptide-specific CD8+ T cell responses but has the
limitation that we can only vaccinate a portion of cancer
patients that express a particular HLA phenotype and that
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CEA-specific CD4+ T cell responses may not be activated.
Therefore, we conducted this phase I clinical study to
evaluate and improve the efficacy of DC-based immuno-
therapy using CEA-pulsed DCs mixed with tetanus toxoid
(TT) and subsequent interleukin (IL)-2 treatment. The
use of whole CEA protein as the source of antigen will
provide potential epitopes recognized by CD4+ and
CD8+ T cells derived from patients with different HLA
phenotypes. TT is a very strong recall antigen and in-
duces a delayed-type hypersensitivity (DTH) response.
We hypothesize that the local DTH response induced
by TT further activates co-injected DCs and promotes
their T cell-stimulating functions. Low-dose IL-2 was
administered subcutaneously following DC vaccination
in this study to further boost and maintain T cell
growth. The results of this clinical study, including the
safety evaluation, clinical status, and immune responses
of patients, are reported.
Methods
Patient characteristics
Twelve patients, 6 from the National Taiwan University
Hospital and 6 from the Tri-Service General Hospital,
were enrolled in this study between 2006 and 2010. This
clinical protocol was approved by the Research Ethics
Committee of the National Taiwan University Hospital
(protocol number 27MD02) and the Institutional Review
Board of the Tri-Service General Hospital/National Defense
Medical Center (protocol number 095-04-003), and further
approved by the Department of Health (currently the
Ministry of Health and Welfare), Taiwan. Signed informed
consent was obtained from each patient before the recruit-
ment. All patients had experienced metastasis from their
primary colorectal cancer and had failed the first-line
chemotherapy regimen containing CPT-11 (irinotecan)
or oxaliplatin. Patients were more than 20 years old
and their serum CEA levels were at least 5-fold higher
than the normal limit. All patients had adequate bone
marrow, liver, and renal function defined as white blood
cell ≥3500/mm3, neutrophil ≥1500/mm3, lymphocyte
≥1000/mm3, platelet ≥100,000/mm3, glutamate oxaloac-
etate transaminase (GOT), and glutamate pyruvic
transaminase (GPT) ≤5-fold of the normal range, biliru-
bin ≤1.5-fold of the normal range, and creatinine ≤2-fold
of the normal range. Patients had appropriate immune
function, defined as IgG ≥614 mg/dL, IgM ≥53 mg/dL
and the DTH test showed positive results (≥5 mm in
diameter). Patient performance status (PS) ranged from 0
to 2 on the ECGO scale. Patients with central nervous sys-
tem metastasis, autoimmune disease, or active/chronic in-
fection and patients who received chemotherapy, steroid,
or biological treatment within 4 weeks before enrollment
were excluded from this study. The complete inclusion
and exclusion criteria of patient selection were listed in
the Additional file 1. Selected patient characteristics are
shown in Table 1.
Preparation of human DCs from peripheral blood
mononuclear cells (PBMCs)
PBMCs derived from apheresis were further enriched by
density gradient centrifugation in lymphocyte separation
medium (Lonza, Basel, Switzerland). The PBMCs were
incubated for 2 h at 37 °C in X-VIVO15 medium
(Lonza) in a plastic flask, and adherent cells were cul-
tured in X-VIVO15 medium containing 2 % heat-
inactivated autologous plasma, 1000 U/mL human
interleukin-4 (IL-4, GMP-grade, Strathmann Biotec AG,
Hannover, Germany), and 500 U/mL granulocyte macro-
phage colony-stimulating factor (GM-CSF, GMP-grade,
GENTAUR Belgium BVBA, Kampenhout, Belgium). On
day 6, loosely attached or floating immature DCs were
collected. The immature DCs were stored in the gas
phase of a liquid nitrogen tank until use. No bacteria,
fungus, mycoplasma, or endotoxin contamination were
detected in any cell culture products. The Gram’s
iodine stain method was used for bacteria contamin-
ation evaluation. The detection of bacteria and fungus
contamination was further performed by a growth-
based rapid microbiological method with the BacT/
ALERT automatic culture system (bioMerieux SA,
Marcy I’Etoile, France). The detection of mycoplasma
contamination was performed using a PCR-based
method (e-Myco plus mycoplasma PCR detection kit,
iNtRON Biotechnology, Kyungki-Do, Korea). The endo-
toxin contamination was determined using a Limius
Amebocyte Lysate QCL-1000 Endotoxin test (Lonza).
Vaccine preparation and vaccination protocol
Thawed immature DCs (3 × 106) were suspended in 1 mL
of X-VIVO15 medium and cultured with 25 μg/mL of
Table 1 Characteristics of enrolled cancer patients
Patient Sex Age PS Metastasis site
1 Male 68 1 Liver, lung, and bone
2 Female 49 1 Liver
3 Female 48 1 Liver
4 Female 62 2 Liver and lung
5 Male 45 1 Rectum
6 Male 58 1 Liver, lung, bone and adrenal glands
7 Male 52 0 Liver
8 Male 48 1 Liver
9 Female 52 1 Liver, lung and bone
10 Male 80 1 Liver, lung, and lymph node
11 Male 65 1 Abdominal wall
12 Male 62 0 Liver
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recombinant human CEA (rhCEA, Protein Sciences
Corp., Meriden, CT, USA) at 37 °C. After 3 h, rhCEA-
pulsed DCs were collected and matured by culturing
the cells in X-VIVO15 medium containing 2 % heat-
inactivated autologous plasma and 1000 U/mL tumor
necrosis factor-α (TNF-α, CELL-GRO, CellGenix, Freiburg
im Breisgau, Germany), recombinant human interferon-
gamma (IFN-γ, GMP-grade, GENTAUR Belgium BVBA),
and human IL-4 (GMP-grade, Strathmann) in a T25 flask
at 37 °C for 18 h. The cells were collected and used as
rhCEA-pulsed, matured DCs. The procedure of pulsing
DCs with rhCEA was modified from a previous study
[24]. In this study, we did not actually verify the effi-
ciency of CEA presentation by DCs pulsed with rhCEA.
Collected DCs were washed five times with normal
saline, and 1.5 × 106 DCs were suspended in 0.3 mL
normal saline supplemented with 1 % heat-inactivated
autologous plasma. To remove cell clusters, the cell
suspension was slowly passed through a 25-gauge needle.
The cell suspension was then injected subcutaneously
near one inguinal lymph node of the patient. For the first
DC vaccine injection, the cell suspension was mixed with
diluted tetanus toxoid (0.04 U in 0.1 mL, Adimmune
Corp., Taichung, Taiwan) before injection. Patients
were vaccinated once per week for 3 weeks followed by a
boost injection 2 weeks later. IL-2 (Proleukin, Chiron,
Emeryville, CA, USA) was injected subcutaneously
(5 × 106 IU/m2, twice/day × 3 days) 1 week after the
fourth DC vaccination. Whole blood (30 mL) was col-
lected from the patients 2 weeks after the first and last
injections. PBMCs were purified and cryopreserved to
evaluate the immune responses against CEA. Patients
received the first CT examination 6 weeks after the
first DC vaccination and every 2 months afterward.
Patients showing stable or better clinical responses re-
ceived 1 boost injection of DC vaccine every 2 months
until disease progression. The schedule of DC vaccin-
ation and treatment of this study is shown in Fig. 1.
Flow cytometry analysis of immature DCs
Immature DCs were stained with different fluorescence-
labeled monoclonal antibodies (mAbs) and then analyzed
using a flow cytometer (FACSCalibur; BD Biosciences,
Franklin Lakes, NJ, USA). The mAbs used in the
study included: FITC-anti-HLA-DR (Beckman Coulter,
Brea, CA, USA), phycoerythrin-anti-CD86 (Beckman
Coulter), FITC-anti-CD80 (Immunotech, Marseille Cedex,
France), phycoerythrin-anti-CD86 (Beckman Coulter),
phycoerythrin-anti-CD83 (Immunotech, Marseille Cedex,
France), phycoerythrin-anti-CD14 (BD Biosciences), and
FITC-anti-CD40 (Biolegend, San Diego, CA, USA).
Isotype-matched control mAbs were obtained from
Biolegend. Results were expressed as the percentage of
cells stained positive for a given mAb.
T-cell proliferation assay
PBMCs collected before and after vaccination were thawed
at the same time for immunologic analysis. Three repli-
cates of 1 × 105 PBMCs were cultured in 96-well culture
plates for 5 days in RPMI-1640 supplemented with 5 % hu-
man type-AB serum (Lonza) in the presence of 0 (PBS), 5,
10, 25, or 50 μg/mL rhCEA protein (Fitzgerald, Fitzgerald
Industries International. Acton, MA, USA). Cellular
proliferation was determined using a bromodeoxyuri-
dine (BrdU) incorporation enzyme-linked immunosorbent
assay (ELISA) kit (Roche Diagnostics GmbH, Mannheim,
Germany). T cell proliferation status was expressed as the
OD value measured at 450 nm (reference wavelength
650 nm). The raw data of T cell proliferation assay was
provided in the Additional file 2.
Toxicity and clinical evaluation
Toxicity grading was conducted and recorded according
to National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE) v4.0. Clinical
tumor responses were defined following the Response
Evaluation Criteria in Solid Tumors v1.0.
Statistical analysis
Data are presented as mean ± SD and differences between
means were analyzed with the Student’s T test using
Fig. 1 Summary of treatment procedures in this study. Enrolled patients
were injected with tetanus toxoid (TT), and those with positive TT DTH
responses were subjected to leukopheresis to generate DCs for
vaccine preparation. Cells were cultured in GM-CSF and IL-4 to
generate immature DCs (day 1, d1). After 6 days, immature DCs
were collected and checked for compliance with QC requirements
(d7). DC preparations passed for QC were thawed on d14 and pulsed
with rhCEA for 3 h and then stimulated with TNF-α and INF-γ for 16 h
to generated mature DCs. Next, 1 × 106 rhCEA-pulsed DCs were injected
subcutaneously into patients on days 15, 22, 29, and 43. For the
first injection, the DC vaccine was mixed with TT. One week after
the last DC vaccine injection (d50), patients were subcutaneously
injected with IL-2 for 3 days (d51–d53). PBMCs were collected before,
during, and after DC vaccination for immune responses analysis. Patients
were subjected to CT examination for clinical responses 6 weeks after
the first DC vaccine injection (d57), and every 2 months afterwards until
disease progression
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Microsoft Excel software (Redmond, WA, USA). Dif-
ferences were considered significant at P < 0.05.
Results
Patients and vaccine preparation
Twelve patients were enrolled and treated in this clinical
study (Table 1). All patients recruited showed proper
bone marrow, liver, kidney, and immune functions and
fit the inclusion and exclusion criteria of this study.
Selected baseline clinical data of these patients are listed
in Tables 2 and 3. These patients all displayed positive
DTH responses against tetanus toxoid after the boosting
injection and had adequate serum IgG and IgM levels
(Table 3), suggesting proper basic immune functions
after previous chemotherapy. The schedule of DC vac-
cination in this study is shown in Fig. 1. The DCs gener-
ated from patients’ mononuclear cells displayed proper
surface markers (more than 80 % positive for HLA-DR,
CD86, and CD40) and met the release criteria of the in-
process cell products (Table 4). For each DC vaccine
preparation, the supernatant from the day 6 DC culture
and supernatant after the last washing were examined
for contamination with endotoxin, mycoplasma, fungus,
and bacteria. All samples analyzed were negative for
microorganism contamination and the endotoxin level
was always below 0.15 endotoxin U/mL. These results in-
dicate that the quality of our vaccine product is adequate.
Adverse events and autoimmune profiles
The primary endpoint of this study was the safety of the
treatment procedure. No severe treatment-related side
effects or toxicity was observed in patients who received
the regular 4 DC vaccine injections. However, patients 2
and 8 showed early disease progression during the treat-
ment period and only received 2 and 3 DC vaccinations,
respectively. Some evaluation data were not available
from these 2 patients because of their early withdrawal
from the study. The remaining 10 patients received at
least 4 standard DC vaccinations and subsequent IL-2
administration. A comparison of liver and kidney func-
tions of the patients before, during, and after DC vaccin-
ation is shown in Table 5. Patients 4 and 8 showed a more
Table 2 Baseline clinical data (1)
Patient CEA Leukocyte Neutrophil Lymphocyte Platelets
1 82.3 4460 3010 1057 310,000
2 323.3 7310 5695 1301 240,000
3 53.5 5280 3559 1362 217,000
4 645.7 7130 4442 2081 207,000
5 391.2 6100 4111 1482 250,000
6 291.7 7700 5328 1371 279,000
7 1388.1 13700 9410 1980 253,000
8 849 7300 4679 1365 229,000
9 500.6 8730 6590 1090 275,000
10 60.3 5970 3647 1528 146,000
11 298.8 9740 7305 1705 350,000
12 28.7 5330 2740 2180 205,000
Table 3 Baseline clinical data (2)
Patient GOT/GPT Bilirubin Creatinine IgG
IgM
DTH skin test
1 26/40 0.89 1 IgG (1170)
IgM (58.4)
16 mm× 15 mm
2 47/38 1.15 0.8 IgG (1330)
IgM (79.8)
10 mm× 7 mm
3 19/14 1.0 0.8 IgG (1530)
IgM (54.9)
5 mm × 5 mm
4 38/19 0.95 0.7 IgG (1890)
IgM (56.2)
30 mm× 30 mm
5 20/23 0.7 1.1 IgG (1320)
IgM (96)
6 mm × 6 mm
6 22/9 0.9 1.2 IgG (1560)
IgM (83)
8 mm × 11 mm
7 43/34 0.4 1.1 IgG (821)
IgM (56)
8 mm × 10 mm
8 50/41 1.4 0.8 IgG (1500)
IgM (64)
10 mm× 8 mm
9 39/15 0.4 0.5 IgG (1150)
IgM (86)
12 mm× 10 mm
10 40/24 0.7 0.8 IgG (1630)
IgM (76)
11 mm× 11 mm
11 19/12 0.53 0.9 IgG (1580)
IgM (83.9)
7 mm × 9 mm
12 25/24 1.5 0.9 IgG (1270)
IgM (93.2)
12 mm× 12 mm
Table 4 Surface marker expression of DC 6 days after culture
from PBMCs
Marker HLA-DR CD86 CD40
Patient
1 93.39a 96.47 98.22
2 95.4 85.36 99.41
3 83.14 94.17 95.51
4 95.2 94.98 96.64
5 97.92 93.64 98.96
6 95.98 87.72 94.75
7 84.4 93.08 97.24
8 86.25 95.35 99.18
9 94.03 96.22 94.54
10 90.67 93.29 97.71
11 89.52 97.43 98.25
12 95.9 93.76 95.97
Mean ± SD 91.8 ± 4.96 93.5 ± 5.34 97.2 ± 1.71
aResults were expressed as the percentage of cells stained positive for a given mAb
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substantial increase in GOT during the study (day 36) and
were subsequently removed from the study because of
disease progression. Several other patients showed minor
elevations in GOT/GPT, but the level remained within the
initial patient selection criteria (5-fold of normal value).
Patient 12 showed a minor increase in bilirubin on day 36,
but returned to the initial level on day 57. Patient 8
showed a substantial increase in bilirubin on day 36 and
was subsequently removed from the study because of
disease progression. Patient 6 showed an increase in cre-
atinine on days 36 and 57, but the level remained within
the initial patient selection criteria (2-fold of normal
value). These detection values were within the limit of
grade II toxicity.
Autoimmune factors, including anti-nuclear antibody,
rheumatoid factor, and thyroglobulin antibody, were not
substantially increased after treatment in most patients.
However, final data were unavailable from three patients
because of disease progression (Table 6). Patient 9
showed a higher level of rheumatoid factor before treat-
ment, and the level slightly decreased during and after
the 4 DC vaccine injections. Patient 12 showed a higher
level of thyroglobulin antibody before treatment, and the
level decreased during and after the 4 DC vaccine injec-
tions. Overall, we observed no significant changes in the
autoimmune profiles of the patients.
In the evaluation of other side effects and toxicity
(Table 7), patient 1 had grade III diarrhea before treat-
ment and the symptom persisted during the trial period.
Patient 2 had grade III diarrhea on day 22, which was
resolved soon after. Patient 6 had grade II creatinine ele-
vation, likely because of bone metastasis of his disease.
Some other minor grade I or II side effects and toxicities
were occasionally observed, but were not persistent or
severe. There was no significant or rapid body weight
loss in patients following DC vaccine injections. Taken to-
gether, these results indicate that the injection of rhCEA-
pulsed DCs into late-stage colorectal cancer patients using
our vaccination process is generally safe.
Clinical and immune responses
In the observation of clinical response of these patients,
patients 5 and 12 showed stable disease after standard
vaccination (Table 8). Therefore, these 2 patients re-
ceived 2 and 1 boosting injection(s), respectively, until
disease progression. The total duration of disease stable
period was 105 and 98 days for patients 5 and 12
(Table 8). The other 10 patients had disease progression
either during the treatment period or at the first evalu-
ation time point after the treatment procedure. The
overall rate of patients with clinical benefit was 16.7 %
for all 12 enrolled patients and 20 % for the 10 patients
completing the standard 4 DC vaccination protocol.
For the investigation of immune responses after DC
vaccination, PBMCs collected before and after DC vac-
cination were thawed at the same time for immuno-
logical analysis. Cells were cultured with 5–50 μg/mL of
rhCEA for 5 days and then cellular proliferation was de-
termined. Blood samples from 9 patients were analyzed
for T cell responses against rhCEA; while blood samples
after treatment were not available from 3 patients because
of early disease progression and patients’ reluctance to
blood drawing, and were therefore not examined for T cell
responses. As shown in Fig. 2, most T cell responses
Table 5 Comparison of liver and kidney function of patients before, during, and after DC vaccination




















1 26/40 40/33 47/37 0.89 1.04 1.35 1.0 1.1 1.0
2 47/38 offa off 1.15 off off 0.8 off off
3 19/14 27/26 54/84 1.0 0.68 0.65 0.8 0.7 0.7
4 38/19 94/37 off 0.95 1.01 off 0.7 0.8 off
5 20/23 17/17 20/39 0.7 1.1 0.5 1.1 1.2 1.0
6 22/9 26/11 22/13 0.9 0.8 1.0 1.2 2.2 2.3
7 24/39 52/55 47/46 0.4 1.2 1.0 1.0 0.9 0.8
8 50/41 132/61 off 1.4 35.5 off 0.8 0.8 off
9 39/15 29/14 41/28 0.4 0.4 0.3 0.5 0.5 0.4
10 32/17 53/30 49/48 0.9 0.8 0.9 0.9 0.8 0.7
11 19/12 20/11 23/14 0.53 0.3 0.33 0.9 0.8 0.8
12 25/24 41/45 28/30 1.5 2.25 1.53 0.9 1.0 1.0
a“off” indicates samples not available for analysis because of withdrawal or termination of enrolled patients from this study
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against rhCEA were not strong. In some of the patients,
addition of rhCEA appears to induce cell death as reflexed
by the significant reduction of BrdU incorporation. Pa-
tients 5 and 12 showed stable disease after standard vac-
cination and therefore received 2 and 1 boosting
injection(s), respectively. The proliferation of T cells
was determined with additional PBMCs collected on day
180 (patient 5) and day120 (patients 5 and 12). A statisti-
cally significant increase in the T cell proliferation against
rhCEA (10 and 50 μg/mL) was observed in patient 12, but
not in patient 5, with PBMCs collected on day 57 and day
120, suggesting the presence of a persistent T cell res-
ponse. A temporary significant increase in T cell prolifera-
tion against rhCEA (10 μg/mL) was observed in patient 9
with PBMCs collected on day 36.
Discussion
The results of this study indicated that the strategy of
combining the DC vaccine with TT followed by low-dose
Table 6 Comparison of autoimmune profiles before, during, and after vaccination



















1 1:40 1:40 1:40 <20 <20 <20 1:40 1:40 1:40
2 1:40 offa off <20 off off 1.7 off off
3 1:40 1:40 1:40 <20 <20 <20 1:40 6.21 1:40
4 1:40 1:80 off <20 <20 off 1:40 1:40 off
5 (−) (−) (−)b <20 22.9 23.3 1:80 1:80 <1:10
6 (−) (−) (−) <20 <20 <20 1:80 <1:10 <1:10
7 (−) (−) (−) <20 <20 <20 1:40 1:80 1:40
8 (−) (−) off <20 <20 off 1:80 1:40 off
9 (−) (−) (−) 60.6 59.5 44.2 1:160 1:80 <1:10
10 1:640 1:>1280 1:>1280 <20 20.5 21.4 1:40 <1:10 1:40
11 1:40 1:40 1:40 <20 <20 <20 5.11 3.09 7.81
12 1:40 1:40 1:40 <20 <20 <20 14.2 0.71 1.14
“off” indicates samples were not available for analysis due to withdraw or termination of enrolled patients from this study
a“off” indicates samples not available for analysis because of withdrawal or termination of enrolled patients from this study
b(−): not detected
Table 7 Frequency and grade of adverse events of the 12 patients
Gradea I II III IV V
Adverse event
Local pain 3/12b 2/12
Local swelling 1/12
Fever 5/12 2/12
Skin rash/itching/skin desquamation 3/12 2/12
Myalgia 1/12
Bilirubin 4/12 1/12 2/12 1/12
GPT 9/12 2/12
GOT 9/12 2/12 1/12
Hemorrhage (UGIc) 1/12








aAdverse event was determined using CTCAE version 4.0
b“3/12” indicates that 3 of 12 patients had at least one episode of a particular
adverse event
cUGI indicates upper gastrointestinal















12 4(1) SD (98 days)
aPD: progressive disease
bSD: stable disease






























































































































Patient 1 Patient 3
Patient 5 Patient 6
Patient 7 Patient 9
Patient 10 Patient 11
Patient 12
Fig. 2 (See legend on next page.)
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IL-2 injection is generally safe for patients with late-stage
CRC. No severe treatment-related toxicity was observed
in any evaluable patients after DC vaccination. The vital
signs of all patients were stable after vaccination. As de-
scribed above, patients 2 and 8 showed early disease
progression during the treatment period and only received
2 and 3 DC vaccinations, respectively. Patient 4 showed
disease progression shortly after completion of the treat-
ment. Some evaluation data were not available from these
patients because of early withdrawal from the study.
Patient 9 showed a higher level of rheumatoid factor
before treatment, and the level slightly decreased during
and after the 4 DC vaccine injections. Patient 12 showed a
higher level of thyroglobulin antibody before treatment,
and the level decreased during and after the 4 DC vaccine
injections. Patient 1 had grade III diarrhea before treat-
ment, and the symptom persisted during the trial period.
Patient 2 had grade III diarrhea on day 22, but this was re-
solved soon after. Patient 6 had grade II creatinine eleva-
tion, likely because of the bone metastasis of his disease.
Some other minor grade I or II side effects or toxicities
were occasionally observed, but were not persistent or
severe.
In this study, we found that vaccination of DCs pulsed
with rhCEA is feasible and safe in the laboratory and
clinical setting. Such vaccination may induce T cell res-
ponses in certain cancer patients. However, these res-
ponses were moderate at best. In patient 12 with stable
disease, the proliferation of T cells against rhCEA was
detected at 57 and 120 days after initial injection. How-
ever, such increase in the T cell proliferation was not
observed in patient 5 who also had stable disease after
treatment. These results suggest that T cell proliferation
against CEA may not be the most adequate method to
determine the immune status in patients of this study,
or the clinical benefit may result from immune re-
sponses against tumor-associated antigens other than
CEA. Addition of rhCEA resulted in death of PBMCs
from several patients in the T cell proliferation assay.
We can not rule out the possibility that this is due to
an antigen-induced apoptosis of T cells.
Attempts to stimulate or maintain a prolonged T cell
response in vaccinated patients have been explored in
many studies. These efforts include improvement of DC
stimulation [25, 26], pre-conditioning of the vaccination
site [27], and measures to maintain a long-lasting T cell
response with cytokines or other biological agents [28].
We previously reported in animal models a strategy for
pulsing DCs with CD40 ligand-transfected tumor cells
and pre-conditioning with MIP-3α-transfected tumor
cells [29, 30]. Both approaches resulted in a better im-
mune response against the tumor and effectively sup-
pressed tumor growth and metastasis. This current
study focused on the incorporation of the recall antigen
TT in vaccine preparation and supplement of cytokines
such as IL-2 after vaccination to increase the longevity of
T cell responses. A recent study using TT to pre-condition
the vaccination site of DCs pulsed with Cytomegalovirus
phosphoprotein 65 RNA to treat glioblastoma patients also
demonstrated an increase in the migration of DCs to
draining lymph node and improved clinical outcomes [31].
Alternatively, strategies for removing or suppressing regu-
latory T cell activity in vivo were shown to enhance the T
cell responses [28]. Another attractive strategy is to isolate
T cells from patients after vaccination, expand and activate
these T cells to a large quantity in vitro, and infuse the acti-
vated T cells back into the patients [32, 33]. The expansion
of T cells in vitro may potentially bypass the negative
influence of regulatory T cells in the body. In addition,
repeated infusions of a large number of tumor-associated
antigen-specific T cells would be possible using this ap-
proach. Thus, a combination of different immunotherapy
strategies, DC vaccination, and adoptive T cell therapy,
may increase the efficacy of cancer treatment [18, 34]. We
are currently investigating the potential of such combined
immunotherapy.
Conclusions
The results of this clinical study were compatible to the
safety data and clinical observation reported for other
cancers involving DC-based immunotherapy [15, 16].
Although the results of our clinical study are encour-
aging, most patients still showed disease progression
during or after the DC vaccination. Additionally, these
12 patients were in the advanced disease stage and had
failed all available treatments before entering this study.
These results strengthen the view that DC-based im-
munotherapy should be performed in patients with early
disease status or combined with other clinical interven-
tions such as anti-immune checkpoint antibodies or
adoptive T cell therapies to obtain better treatment
outcomes.
(See figure on previous page.)
Fig. 2 Proliferation against rhCEA by PBMCs collected before, during, and after DC vaccination from different patients. PBMCs collected before
(day 0), during, and after DC vaccination (days 36, 57, 120, and 180) were cultured in 96-well culture plates for 5 days in the presence of 0 (PBS),
5, 10, 25, or 50 μg/mL rhCEA. Cellular proliferation was determined using a BrdU incorporation ELISA. T cell proliferation status was expressed as
the OD value measured at 450 nm (reference wavelength 650 nm). The OD value obtained from culture with different concentrations of rhCEA
was compared to that of culture with PBS control. *p < 0.05, **p < 0.001
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